The pooled HR of 1.79 (95% CI, 0.91-3.53) for PFS in a fixed-effect model (I2=0%; P=0.893) suggested that PIK3CA mutant NSCLC patients had similar PFS compared with wild-type patients when treated with EGFR-TKIs (Figure 5B). This evidence concerns the gene EGFR and non-small cell lung carcinoma.